

Response to: 'Is chondroitin sulfate plus glucosamine superior to placebo in the treatment of knee osteoarthritis?' by Zeng *et al*

We would like to thank Zeng *et al*¹ for their comments on the Multicentre Osteoarthritis interVENTion trial with SYSADOA (MOVES)² and the Glucosamine/chondroitin Arthritis Intervention Trial (GAIT)³ and its long-term follow-up.⁴

In MOVES,² glucosamine plus chondroitin sulfate was non-inferior to celecoxib (primary outcome: mean decrease in Western Ontario and McMaster (WOMAC) pain score) in 606 patients with knee osteoarthritis with moderate-severe pain. A placebo arm was not included because celecoxib, the reference treatment, had proven efficacy versus placebo in knee osteoarthritis, for example^{5, 6}; so, this was felt to be unethical and unnecessary. While Zeng *et al*¹ agreed with this decision, they brought up some interesting points.

The original 24-week randomised, controlled GAIT trial³ compared the effects of glucosamine and/or chondroitin sulfate, celecoxib and placebo on knee osteoarthritis pain. There was a significant benefit of glucosamine plus chondroitin sulfate over placebo (primary outcome: 20% decrease in WOMAC pain score at 24 weeks) among a prespecified subgroup of patients with moderate-severe pain. The 24-month GAIT follow-up,⁴ as Zeng *et al*¹ pointed out, failed to demonstrate significant differences between treatment arms. However, the 24-week GAIT trial³ included 1583 patients (1258 (79%) completed the study), while the 24-month follow-up⁴ only included 662 patients (349 (only 53%) completed). Furthermore, GAIT was designed and powered (sample size required: 1270) to examine efficacy over 24 weeks, not 24 months. The long-term extension study was found to be underpowered, with an unusually high dropout rate and very low pain levels at baseline; therefore, the results of GAIT³ were likely to be more reliable than those of the follow-up study.⁴

Zeng *et al*¹ also mentioned the Long-term Evaluation of Glucosamine Sulfate (LEGS) study,⁷ which randomised 605 patients with knee osteoarthritis to glucosamine and/or chondroitin sulfate or placebo. LEGS⁸ found that glucosamine plus chondroitin sulfate significantly reduced joint space narrowing, but not pain, versus placebo (there were two primary outcomes). However, direct comparison of the results of MOVES² and LEGS⁷ was not possible as there were important differences in study design because the LEGS study⁷ examined joint space narrowing while MOVES² studied pain. Patients in LEGS⁷ had less severe pain than those in MOVES² (baseline mean standardised WOMAC pain 33.5 vs 74.2). In addition, patients in LEGS could use non-steroidal anti-inflammatory drugs or opioid analgesics throughout the study, which could have masked any pain differences between groups, while in MOVES, patients could only take acetaminophen as rescue, but not in the 24 h before clinical evaluation. Lastly, MOVES used pharmaceutical-quality chondroitin sulfate and glucosamine (Bioiberica SA, Barcelona, Spain), whereas the products used in LEGS were dietary supplements. As discussed in a recent publication,⁸

the source and purity of these extracted natural products are important, and not all products have the same efficacy.

Zeng *et al*¹ also pointed out that some studies of glucosamine and chondroitin sulfate included manganese ascorbate, which could have improved efficacy. It is always difficult to compare between different studies, which is why the results of GAIT,³ which directly compare glucosamine plus chondroitin sulfate with placebo and show a significant effect among those with moderate-severe pain at 24 weeks, are important. MOVES² supported this result by showing a pain response to glucosamine and chondroitin sulfate that was non-inferior to celecoxib.

Marc C Hochberg, on behalf of the MOVES Investigation Group

University of Maryland School of Medicine, Baltimore, Maryland, USA

Correspondence to Professor Marc C Hochberg, University of Maryland School of Medicine, 10 S. Pine St., MSTF 8-34, Baltimore, MD 21201, USA; mhochber@medicine.umaryland.edu

Competing interests MCH is a consultant to Bioiberica SA, Bristol Myers Squibb, Eli Lilly, EMD Serono SA, Iroko Pharmaceuticals, Novartis Pharma AG, Pfizer, Samumed and Theralogix, and owns stock in Theralogix.

Provenance and peer review Commissioned; internally peer reviewed.



CrossMark

To cite Hochberg MC, on behalf of the MOVES Investigation Group. *Ann Rheum Dis* 2015;**74**:e57.

Received 16 March 2015

Accepted 23 March 2015

Published Online First 25 May 2015



► <http://dx.doi.org/10.1136/annrheumdis-2015-207476>

Ann Rheum Dis 2015;**74**:e57. doi:10.1136/annrheumdis-2015-207482

REFERENCES

- 1 Zeng C, Wei J, Lei G-h. Is chondroitin sulfate plus glucosamine superior to placebo in the treatment of knee osteoarthritis? *Ann Rheum Dis* 2015;**74**:e37.
- 2 Hochberg MC, Martel-Pelletier J, Monfort J, *et al*. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. *Ann Rheum Dis* 2015. Published Online First: 14 Jan 2015. doi:10.1136/annrheumdis-2014-206792
- 3 Clegg DO, Reda DJ, Harris CL, *et al*. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. *N Engl J Med* 2006;**354**:795–808.
- 4 Sawitzke AD, Shi H, Finco MF, *et al*. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. *Ann Rheum Dis* 2010;**69**:1459–64.
- 5 Laine L, White WB, Rostom A, *et al*. COX-2 selective inhibitors in the treatment of osteoarthritis. *Semin Arthritis Rheum* 2008;**38**:165–87.
- 6 Hochberg MC, Fort JG, Svensson O, *et al*. Fixed-dose combination of enteric-coated naproxen and immediate-release esomeprazole has comparable efficacy to celecoxib for knee osteoarthritis: two randomized trials. *Curr Med Res Opin* 2011;**27**: 1243–53.
- 7 Fransen M, Agaliotis M, Nairn L, *et al*. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. *Ann Rheum Dis* 2015;**74**:851–8.
- 8 Martel-Pelletier J, Farran A, Montell E, *et al*. Discrepancies in composition and biological effects of different formulations of chondroitin sulfate. *Molecules* 2015;**20**:4277–89.